Correlation Between Inhibrx and Humacyte
Can any of the company-specific risk be diversified away by investing in both Inhibrx and Humacyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and Humacyte into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibrx and Humacyte, you can compare the effects of market volatilities on Inhibrx and Humacyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of Humacyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and Humacyte.
Diversification Opportunities for Inhibrx and Humacyte
Pay attention - limited upside
The 3 months correlation between Inhibrx and Humacyte is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and Humacyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Humacyte and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with Humacyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Humacyte has no effect on the direction of Inhibrx i.e., Inhibrx and Humacyte go up and down completely randomly.
Pair Corralation between Inhibrx and Humacyte
Given the investment horizon of 90 days Inhibrx is expected to under-perform the Humacyte. But the stock apears to be less risky and, when comparing its historical volatility, Inhibrx is 2.44 times less risky than Humacyte. The stock trades about -0.01 of its potential returns per unit of risk. The Humacyte is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest 161.00 in Humacyte on August 31, 2024 and sell it today you would earn a total of 10.00 from holding Humacyte or generate 6.21% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Flat |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
Inhibrx vs. Humacyte
Performance |
Timeline |
Inhibrx |
Humacyte |
Inhibrx and Humacyte Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Inhibrx and Humacyte
The main advantage of trading using opposite Inhibrx and Humacyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, Humacyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Humacyte will offset losses from the drop in Humacyte's long position.Inhibrx vs. Crinetics Pharmaceuticals | Inhibrx vs. Merus BV | Inhibrx vs. Lyell Immunopharma | Inhibrx vs. Kronos Bio |
Humacyte vs. Cue Biopharma | Humacyte vs. Eliem Therapeutics | Humacyte vs. Inhibrx | Humacyte vs. Molecular Partners AG |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Complementary Tools
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
CEOs Directory Screen CEOs from public companies around the world | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |